Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900828 | 0.82 | KMT2A (0.33) | — | |
| SCHEMBL1819088 | 0.82 | IRAK4 (0.39) | ALDH1A1GAA | |
| SCHEMBL6204505 | 0.78 | — | — | |
| SCHEMBL10634679 | 0.78 | TSHR (0.31) | — | |
| SCHEMBL160523 | 0.77 | — | — | |
| SCHEMBL9030694 | 0.76 | MAPT (0.33) | — | |
| SCHEMBL9673372 | 0.76 | CA1 (0.37) | — | |
| SCHEMBL16467762 | 0.76 | — | — | |
| SCHEMBL22729269 | 0.76 | TRPA1 (0.35) | — | |
| SCHEMBL15474650 | 0.76 | CYP3A4 (0.36) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | claimed |
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | claimed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | claimed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | claimed |
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | claimed |
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-20 | — | — | US | claimed |
| EP-1758583-A2 | ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-03-07 | — | — | EP | claimed |
| EP-1682145-A1 | 1-ALKYLPIPERAZINYL-PYRROLIDIN-2,5-DIONE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2006-07-26 | — | — | EP | claimed |
| WO-2005118537-A2 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | claimed |
| WO-2005037282-A1 | 1-ALKYLPIPERAZINYL-PYRROLIDIN-2,5-DIONE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-28 | — | — | WO | claimed |
| US-6448259-B1 | CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY | NEUROGEN CORPORATION | 2002-09-10 | — | — | US | claimed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | disclosed |
| EP-1758583-A2 | ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118537-A2 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | disclosed |
| US-4379788-A | HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | ADRA1D, ADRA1A, ADRB1 | ALDH1A1 51/4885GAA 2808/4885 |
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | ADRA1D, ADRB1, ADRA1A | ALDH1A1 50/4885GAA 2279/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | ALDH1A1 2405/4885GAA 1201/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | ALDH1A1 2405/4885GAA 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.